CARLSBAD, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2025 financial results after market close on Thursday, August 28, 2025. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time.
Related Questions
What were Carlsmed's Q2 2025 revenue and earnings compared to consensus estimates?
Did management provide guidance for Q3 2025 or FY 2025, and how does it compare to prior forecasts?
How are the AI-enabled spine surgery solutions performing in terms of adoption and market traction?
What is the impact of any new product launches or regulatory approvals mentioned in the call on future sales?
Are there any changes to the company's capital allocation strategy, such as R&D spending or M&A activity?
What is the cash flow outlook for the next quarters, and does the company have sufficient liquidity to fund growth initiatives?
Did the company address any competitive threats or emerging technologies that could affect its market position?
What are the potential upside or downside risks highlighted by management that could influence the stock price?
How does Carlsmed's gross margin and operating margin trend compare to its peers in the medical technology sector?
How might the Q2 results affect the valuation multiples (e.g., P/E, EV/EBITDA) relative to the broader market and sector peers?